Results of secondary outcomes.
| Outcomes | No. Studies | No. Participants, CYC/MMF | RR (95% CI) | I2, % |
|---|---|---|---|---|
| Leukopenia | 3 | 243/235 | 1.29 (0.35 to 4.70) | 81 |
| Infections | 4 | 310/308 | 1.56 (0.66 to 3.69) | 87 |
| Gastrointestinal | 4 | 310/308 | 0.74 (0.54 to 1.02) | 0 |
| Herpes zoster | 4 | 310/308 | 0.88 (0.43 to 1.80) | 30 |
| Amenorrhea | 4 | 310/308 | 6.64 (2.00 to 22.07) | 0 |
| Alopecia | 3 | 285/289 | 5.77 (1.56 to 21.38) | 36 |
| ESRD* | 4 | 310/308 | 2.06 (1.07 to 3.98) | 0 |
| ESRD (study period) | 2 | 210/204 | 1.29 (0.22 to 7.63) | 39 |
| ESRD (longterm followup) | 3 | 125/123 | 2.24 (0.80 to 6.30) | 0 |
| Death* | 4 | 310/308 | 1.15 (0.47 to 2.82) | 22 |
| Death (study period) | 3 | 279/275 | 1.07 (0.14 to 8.03) | 47 |
| Death (longterm followup) | 3 | 125/123 | 2.00 (0.73 to 5.43) | 0 |
↵* ESRD and death ever reported (during study period and followup). MMF: mycophenolate mofetil; CYC: cyclophosphamide; RR: relative risk; ESRD: endstage renal disease.